Tesamorelin (brand name Egrifta) is an FDA-approved GHRH analog with a specific clinical indication: reduction of visceral adipose tissue (VAT) in HIV-associated lipodystrophy. It is the only peptide in existence with FDA approval specifically targeting visceral fat reduction — and the clinical data behind this approval provides a uniquely robust evidence base for its metabolic applications.

The Trans-3-Hexenoic Acid Modification

Tesamorelin is synthesized by conjugating human GHRH(1-44) — the complete 44-amino acid GHRH sequence, unlike sermorelin which uses only 1-29 — with trans-3-hexenoic acid at the N-terminus. This modification dramatically extends the peptide's half-life and metabolic stability: - Native GHRH: ~7 minutes half-life (rapidly cleaved by DPP-IV) - Tesamorelin: ~30 minutes half-life — matching CJC-1295 No DAC without the amino acid substitutions

The complete 1-44 sequence plus the N-terminal fatty acid conjugation creates a compound with slightly different receptor kinetics than sermorelin (1-29) — thought to contribute to tesamorelin's particularly pronounced visceral fat selectivity.

FDA Approval and Clinical Evidence

Tesamorelin received FDA approval in 2010 based on two Phase 3 pivotal trials: - Study 1 (n=412, 26 weeks): 15.2% reduction in visceral adipose tissue vs. 1.4% placebo increase — net difference of ~16.6% - Study 2 (n=273, 26 weeks): 17.8% VAT reduction vs. 0.5% increase in placebo - Secondary endpoints: Improved triglycerides (-40 to -50 mg/dL), reduced LDL:HDL ratio, improved insulin sensitivity - Trunk fat reduction correlated with improved quality of life scores

At 52 weeks (extension study), continuous tesamorelin maintained the VAT reduction — demonstrating sustained efficacy without tolerance development.

Why Visceral Fat Specifically?

The selective visceral fat reduction is mechanistically significant. Tesamorelin stimulates GH release, which then signals adipocytes through the GH receptor. Visceral adipocytes (intra-abdominal fat) express the highest density of GH receptors of any fat depot — making them proportionally more sensitive to GH-mediated lipolysis than subcutaneous fat. This receptor density difference explains why tesamorelin produces proportionally greater visceral vs. subcutaneous fat reduction.

Visceral fat is metabolically distinct from subcutaneous fat — it is more metabolically active, more strongly associated with insulin resistance, inflammation, cardiovascular disease, and type 2 diabetes, and it produces more adipokines and inflammatory cytokines. Reducing visceral fat specifically provides greater metabolic benefit per kilogram lost than subcutaneous fat reduction.

Metabolic and Cardiovascular Benefits

Beyond VAT reduction, tesamorelin Phase 3 data documented: - Triglycerides: -40 to -50 mg/dL (significant cardiovascular risk reduction) - Total cholesterol/HDL ratio: improved - Liver fat: reduction in subjects with hepatic steatosis (NAFLD/NASH) - C-reactive protein: modest reduction (marker of systemic inflammation) - IGF-1: increased in parallel with GH stimulation (downstream anabolic effects)

Tesamorelin vs. Ipamorelin/CJC for Visceral Fat

Tesamorelin's advantage over the Ipamorelin/CJC-1295 combination is specifically its FDA approval and dedicated clinical evidence for visceral fat. The mechanism (GH stimulation → visceral adipocyte lipolysis) is shared by all GHRH analogs, but tesamorelin is the only one with prospective clinical trial data quantifying the visceral fat reduction effect specifically.